TLR8 agonist 10 

TLR8 agonist 10 is a selective TLR8 agonist with an EC₅₀ of 0.019 μM in humans. TLR8 agonist 10 activates TLR8-mediated signaling pathways. As a latency-reversing agent, TLR8 agonist 10 reactivates latent HIV-1 reservoirs. TLR8 agonist 10 activates innate cytotoxic natural killer cells to target HIV-infected CD4⁺ T cells. TLR8 agonist 10 is applicable to research related to HIV-1 infection^[1].

TLR8 agonist 10 (Compound 23A) (0-10 μM) potently reactivates latent HIV-1 in U1 cells in vitro without significant cytotoxicity^[1].
TLR8 agonist 10 (0-10 μM) can indirectly activate latent HIV-1 in ACH-2 cells via cytokine signals produced by treated human PBMCs, and exhibits no significant cytotoxicity against ACH-2 cells^[1].
TLR8 agonist 10 (0-10 μM) potently reactivates latent HIV-1 in OM10.1 cells in a concentration-dependent manner, with no significant cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TLR8 agonist 10 (1-5 mg/kg; i.v., p.o.; single dose) exhibits favorable pharmacokinetic properties in male SD rats, with a long half-life, low clearance, and 35% oral bioavailability after a 5 mg/kg oral dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

326.48

C₂₀H₃₀N₄

2796210-93-8

CCCCNC1=CC(CC2=CC=C(C=C2)CN(C)C)=C(N=C1N)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang Z, et al. Rational Design and Identification of Highly Selective TLR8 Agonists as Potent HIV-1 Latency Reversal Agents. J Med Chem. 2026;69(5):5405-5424.  [Content Brief]